Search
Hydrocortamate
go.drugbank.com/drugs/DB00769ApprovedGlucocorticoids are a class of steroid hormones characterised by an ability to bind with the cortisol receptor and trigger a variety of important cardiovascular, metabolic, immunologic and homeostatic
Ferric sulfate
go.drugbank.com/drugs/DB11171ApprovedIt is produced by the reaction of sulfuric acid and an oxidizing agent. … [A32355, A32356] By the FDA, ferric sulfate is a direct food substance affirmed in the GRAS category (Generally Recognized As Safe).[L2003]
Betula pendula tar oil
go.drugbank.com/drugs/DB11361ApprovedNutraceuticalThis oil is usually obtained by using both hydrodistillation and micro-distillation[A33154] and it is conformed mainly by [DB11143] and [DB11359]. … [L1113] By the FDA, it is considered under the substances approved to be added to the food.
Rusfertide
go.drugbank.com/drugs/DB17724ApprovedInvestigational[L64098] Rusfertide is administered by subcutaneous injection and titrated to maintain hematocrit below 45%.
Albiglutide
go.drugbank.com/drugs/DB09043ApprovedInvestigationalWithdrawnAlbiglutide was approved on April 15, 2014 by the FDA. … It is marketed under the brands Eperzan and Tanzeum by GSK (GlaxoSmithKline). It is a dipeptidyl peptidase-4-resistant glucagon-like peptide-1 dimer fused to human albumin.
Magnesium citrate
go.drugbank.com/drugs/DB11110ApprovedInvestigational[T215] Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the specifications of oral administration of a maximum concentration of 237 mg.
Glutathione disulfide
go.drugbank.com/drugs/DB03310ApprovedA GLUTATHIONE dimer formed by a disulfide bond between the cysteine sulfhydryl side chains during the course of being oxidized.
Levomilnacipran
go.drugbank.com/drugs/DB08918ApprovedInvestigational[L47946] First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults.
Prademagene zamikeracel
go.drugbank.com/drugs/DB17895ApprovedInvestigational[L53013] It was granted an Orphan Drug designation by the EMA.[A273833] … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering
Satralizumab
go.drugbank.com/drugs/DB15762ApprovedInvestigational[A218546,A218551] Satralizumab is thought to exert its therapeutic benefits by blocking IL-6 receptors and, subsequently, these inflammatory responses. … [A218551] Some of the pro-inflammatory mechanisms involved in NMOSD are thought to be mediated, at least in part, by IL-6, including increased production of anti-aquaporin-4 (AQP4) autoantibodies and increased